Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

As curative bone marrow transplantation is available only to a minority of patients with chronic myelogenous leukemia (CML), drug therapy remains of central interest. Several nonrandomized studies have suggested that interferon-alpha (IFN) may prolong survival in CML. In a randomized multicenter study the influence of IFN versus busulfan or hydroxyurea (HU) on survival of Philadelphia-positive (Ph+) CML was examined. A total of 513 Ph+ patients were randomized for treatment as follows: 133 for IFN, 186 for busulfan, and 194 for HU. IFN-treated CML patients have a significant survival advantage over busulfan-treated (P = .008), but not over HU-treated patients (P = .44). The longer survival is due to slower progression to blast crisis. Median survival of IFN-treated patients is 5.5 years [5-year survival, 59%; 95% confidence interval (CI), 48%-70%], of busulfan-treated patients, 3.8 years (5-year survival, 32%; CI, 24%-40%), and of HU-treated patients, 4.7 years (5-year survival, 44%; CI, 36%-53%). Patients who continue on IFN survive longer than those in whom IFN is discontinued before blast crisis (P = .007). Complete hematologic IFN-responders have a survival advantage over partial responders or nonresponders (P = .02). Cytogenetic IFN-responders have no significant survival advantage over nonresponders (P = .2). Patients who attain white blood cell (WBC) counts of 10 x 10(9)/L or less have a survival advantage in the IFN (P = .007) and HU (P = .05) groups. Whereas toxicity in the IFN group was considerably higher than in the busulfan or HU groups, long-lasting cytopenias necessitating discontinuation of therapy as observed with busulfan have not been seen with IFN or HU. The problems of conventional prognostic scores (Sokal's score, Score 1) that we observed in IFN-treated patients support the idea that IFN changes the natural course of CML. We conclude that, with regard to survival of CML in the chronic phase, IFN is superior to busulfan and as effective as HU. Whether and to what extent IFN is superior to HU appears to depend, at least in part, on the degree of WBC suppression by HU-therapy and on the risk profile of the patients.

[1]  C. Peschel,et al.  Regulation of the cytokine network by interferon: a potential mechanism of interferon in chronic myelogenous leukemia. , 1993, Seminars in hematology.

[2]  Rainer Frentzel-Beyme,et al.  Atlas of Cancer Mortality in the Federal Republic of Germany , 1984 .

[3]  C. Bloomfield,et al.  Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583 , 1993 .

[4]  G. Stark,et al.  The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction , 1993, Nature.

[5]  P K Andersen,et al.  Conditional power calculations as an aid in the decision whether to continue a clinical trial. , 1987, Controlled clinical trials.

[6]  Clinical investigation of human alpha interferon in chronic myelogenous leukemia. , 1987 .

[7]  H. Kantarjian,et al.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. , 1986, The New England journal of medicine.

[8]  R. Kurzrock,et al.  Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. , 1991, Annals of internal medicine.

[9]  J. Tanzer,et al.  Quantitative determination of the hybrid Bcr‐Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy , 1992, British journal of haematology.

[10]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[11]  G. Canellos,et al.  Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.

[12]  H. Hochkeppel,et al.  Treatment of anti‐recombinant interferon‐alpha 2 antibody positive CML patients with natural interferon‐alpha , 1991, British journal of haematology.

[13]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[14]  H. Heimpel,et al.  Chronic myelogenous leukemia : recent developments in prognostic evaluation and chemotherapy , 1992 .

[15]  R Simon,et al.  A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.

[16]  Nathan Mantel,et al.  Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .

[17]  R C Young,et al.  Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. , 1975, Blood.

[18]  Z. Estrov,et al.  Chronic Myelogenous Leukemia : A Concise Update , 2003 .

[19]  J. Gutterman,et al.  Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. , 1983, Blood.

[20]  E. Thiel,et al.  Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction , 1991, The Lancet.

[21]  P. Lengyel.  Tumor-suppressor genes: news about the interferon connection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Griffin.  Management of chronic myelogenous leukemia. , 1986, Seminars in hematology.

[23]  B. Efron.  Forcing a sequential experiment to be balanced , 1971 .

[24]  N. Kamada,et al.  Molecular elimination of the minimal residual Ph1 clone with IFNα in CML , 1992, The Lancet.

[25]  E. Thomas,et al.  Indications for marrow transplantation in chronic myelogenous leukemia. , 1989, Blood.

[26]  Xin-Yuan Fu.  A transcription factor with SH2 and SH3 domains is directly activated by an interferon α-induced cytoplasmic protein tyrosine kinase(s) , 1992, Cell.

[27]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Hehlmann,et al.  Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group. , 1994, Leukemia.

[29]  Pepe,et al.  Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. , 1993, Blood.

[30]  F. Grignani,et al.  Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. , 1988, Blood.

[31]  H. Heimpel,et al.  Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. , 1993, Blood.

[32]  J. Gutterman,et al.  Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. , 1983, Annals of internal medicine.

[33]  S. Seeber,et al.  Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma. , 1991, Blood.

[34]  R. Kurzrock,et al.  Clinical toxicity of interferons in cancer patients: a review. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Isaacs,et al.  CHRONIC MYELOGENOUS LEUKEMIA: AGE INCIDENCE, DURATION, AND BENEFIT DERIVED FROM IRRADIATION , 1924 .

[36]  C. Fonatsch,et al.  Recombinant human interferon (IFN) alpha‐2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti‐interferon antibodies , 1989, British journal of haematology.